Pfizer And J&J Settle Remicade Antitrust Litigation
Long-Running Case Over Infliximab Biosimilars Resolved On Confidential Terms
Pfizer and Johnson & Johnson have settled long-running US antitrust litigation over claims that contracts and deals for the Remicade brand were set up to dampen competition from infliximab biosimilars.
You may also be interested in...
Despite commercial success in biosimilars, Pfizer said it is more interested in investing in innovative therapeutics.
Pfizer is looking for the Biden administration’s co-operation to address the policy issue of affordability and access to biosimilars. In the first quarter, the company’s biosimilars segment grew by 84% on the back of new launches, especially in the US where biosimilars sales nearly doubled.
Celltrion and Pfizer are now two for two in their legal battles with Janssen over US patents shielding the originator's Remicade (infliximab), with a US Court of Appeals once again siding with the biosimilars developers.